Please provide your email address to receive an email when new articles are posted on . Direct-to-consumer testing, combined with clinical follow-up, helped identify patients with undiagnosed alpha-1 ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Elevated Z polymer levels may predict lung and liver disease activity in patients with alpha 1 ...

AAT is produced by the liver but helps the lungs defend against inflammation and outside irritants such as smoke or other environmental exposures. “COPD prevalence is especially high in the veteran ...

Boosting levels of a deficient protein has clear survival benefits for people with the genetic condition alpha-1 antitrypsin deficiency (AATD), according to new research led by RCSI University of ...

ORLANDO, Fla.--(BUSINESS WIRE)--Today, The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, announced ...

Alpha-1-antitrypsin is a so-called protease inhibitor, a type of enzyme inhibitor. It is produced in the liver but exerts its effects in the lungs, where it regulates immune cell activity. This ...

- Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide ...

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation ...

Alpha-1 antitrypsin deficiency (AATD) is a genetic disease wherein the individual has a greater risk of developing chronic obstructive pulmonary disease (COPD), liver disease, and skin problems such ...

BEAM-302 demonstrated safety and efficacy in increasing AAT levels and reducing mutant protein in alpha-1 antitrypsin deficiency patients. Beam Therapeutics announced promising initial results from ...

PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and ...